Evidence map›Paper›PMID 36414694›Full record

Observational studyScientific reports2022

EEG-based grading of immune effector cell-associated neurotoxicity syndrome.

Daniel K Jones, Christine A Eckhardt, Haoqi Sun, Ryan A Tesh, Preeti Malik, Syed Quadri, Marcos Santana Firme, Meike van Sleuwen, Aayushee Jain, Ziwei Fan and 11 more

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniel K Jones *Department of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA. Djones51@mgh.harvard.edu.
Christine A Eckhardt *Department of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA. CECKHARDT@PARTNERS.ORG.
Haoqi SunDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Ryan A TeshDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Preeti MalikDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Syed QuadriDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Marcos Santana FirmeDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Meike van SleuwenDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Aayushee JainDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Ziwei FanDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Jin JingDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Wendong GeDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Fábio A NascimentoDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Irfan S SheikhDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Caron JacobsonDepartment of Neurology, Brigham and Women's Hospital (MGH), Boston, MA, USA.
Matthew FrigaultDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Eyal Y KimchiDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Sydney S CashDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
Jong Woo LeeHarvard Medical School, Boston, MA, USA.
Jorg DietrichDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.
M Brandon WestoverDepartment of Neurology, Massachusetts General Hospital (MGH), 50 Staniford St. Suite 401, Boston, MA, USA.

Funding

Neuroscience Resident Research ProgramR25NS065743 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CASH, SYDNEY S, WILLIAMS, ZIV · 2009 to 2023
$11.8M
Comparative Safety of Seizure Prophylaxis within the Medicare ProgramR01AG073410 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Lidia Maria Veras Rocha de Moura · 2021 to 2026
$4.1M
Integrative Motor Activity Biomarker for the Risk of Alzheimer's RiskRF1AG064312 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, KUN · 2019 to 2019
$3.6M
Multimodal Network Connectivity Architecture (MOCA) of the Brain and its Role in the Recovery of Consciousness in Comatose Cardiac Arrest PatientsR01NS102574 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI GREER, DAVID MATTHEW, WU, ONA · 2018 to 2022
$3.4M
Investigation of Sleep in the Intensive Care Unit (ICU-SLEEP)R01NS102190 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WESTOVER, MICHAEL BRANDON · 2018 to 2022
$3.2M
Big Data and Deep Learning for the Interictal-Ictal-Injury ContiuumR01NS107291 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WESTOVER, MICHAEL BRANDON · 2018 to 2022
$2.8M
Neuroscience Resident Research ProgramUE5NS065743 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SYDNEY S CASH, Ziv Williams · 2024 to 2026
$2.6M
NIA NIH HHS R01 AG073410NIA NIH HHS RF1 AG064312NIDDK NIH HHS K08-MH116135NIH HHS R01 AG062989NINDS NIH HHS R01 NS102190NINDS NIH HHS R01 NS102574NINDS NIH HHS R01 NS107291NINDS NIH HHS R25 NS065743NINDS NIH HHS UE5 NS065743
6 · The paper itself

Abstract

CAR-T cell therapy is an effective cancer therapy for multiple refractory/relapsed hematologic malignancies but is associated with substantial toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Improved detection and assessment of ICANS could improve management and allow greater utilization of CAR-T cell therapy, however, an objective, specific biomarker has not been identified. We hypothesized that the severity of ICANS can be quantified based on patterns of abnormal brain activity seen in electroencephalography (EEG) signals. We conducted a retrospective observational study of 120 CAR-T cell therapy patients who had received EEG monitoring. We determined a daily ICANS grade for each patient through chart review. We used visually assessed EEG features and machine learning techniques to develop the Visual EEG-Immune Effector Cell Associated Neurotoxicity Syndrome (VE-ICANS) score and assessed the association between VE-ICANS and ICANS. We also used it to determine the significance and relative importance of the EEG features. We developed the Visual EEG-ICANS (VE-ICANS) grading scale, a grading scale with a physiological basis that has a strong correlation to ICANS severity (R = 0.58 [0.47-0.66]) and excellent discrimination measured via area under the receiver operator curve (AUC = 0.91 for ICANS ≥ 2). This scale shows promise as a biomarker for ICANS which could help to improve clinical care through greater accuracy in assessing ICANS severity.

Indexed as

Hematologic NeoplasmsNeurotoxicity SyndromesReceptors, Chimeric AntigenBiomarkersElectroencephalographyHumansNeoplasm Recurrence, LocalBiomarkersReceptors, Chimeric Antigen

Identifiers

PMID36414694
PMCPMC9681864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.